January 5, 2022 – Thermo Fisher Scientific Inc. completed its acquisition of PeproTech, Inc. (Cranbury, NJ) on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.
PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models.
PeproTech’s recombinant proteins portfolio complements Thermo Fisher’s cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering, the company said.
PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.
“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer.”